Dr. Reddy's Laboratories Limited — Updates, 13-03-2025: Press Release

Dr. Reddy's Laboratories is recalling a specific batch of Levetiracetam in 0.75% Sodium Chloride Injection, due to mislabeling of infusion bags. The recalled product incorrectly states that it is a 500 mg/100 mL dose instead of the correct 1,000 mg/100 mL concentration. This mislabeling poses significant risks, including the potential for patients to receive double the intended dose, which could lead to serious side effects such as hypersensitivity reactions and respiratory depression. The batch in question, Lot No: A1540076, was distributed to wholesalers in the U.S. between early November 2024. While no adverse events related to this issue have been reported, Dr. Reddy’s has urged all users of the affected products to cease distribution and quarantine the items immediately. This recall underscores the importance of accuracy in pharmaceutical labeling. Investors should monitor developments closely, as recalls can impact brand reputation and financial performance.